HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience.

AbstractAIMS:
To assess the long-term outcomes of patients treated with sirolimus-eluting Stentys stent in a real-life setting.
BACKGROUND:
Few data regarding the safety and effectiveness of self-apposing sirolimus-eluting Stentys stent are available.
METHODS:
278 patients (30% stable coronary artery disease, 70% acute coronary syndromes, and 54% on unprotected left main) treated with sirolimus eluting Stentys stent were retrospectively included in the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease multicenter registry. Major adverse cardiovascular events (MACE, a composite of cardiac death, myocardial infarction, target lesion revascularization, stent thrombosis) were the primary end-point, single components of MACE were the secondary ones.
RESULTS:
After 13 months (interquartile range 5-32), MACE was 14%. Stent thrombosis occurred in 3.9% of the patients (2.5% definite stent thrombosis and 1.4% probable stent thrombosis), 66% of them presenting with ST-segment elevation myocardial infarction (STEMI) at admission. Cardiovascular death, target lesion revascularization and myocardial infarction was 4.7%, 8.3%, and 7.2%, respectively. At multivariate analysis, risk of MACE was increased by diabetes (hazard ratios 4.76; P = 0.002) but was not affected by the indication leading to sirolimus-eluting Stentys stent implantation (marked vessel tapering vs. coronary ecstasies, hazard ratios 0.74, P = 0.71).
CONCLUSION:
Sirolimus-eluting Stentys stent may represent a potential solution for specific coronary anatomies such as bifurcation, ectasic, or tapered vessels. Risk of stent thrombosis appears related to clinical presentation with STEMI and to anatomic features, stressing the importance of the use of intracoronary imaging for self-expandable stents implantation.
AuthorsAntonio Montefusco, Ovidio De Filippo, Sebastiano Gili, Massimo Mancone, Simone Calcagno, Plinio Cirillo, Giovanni Esposito, Arnaldo Poli, Erika Ferrara, Grzegorz Smolka, Wojciech Wanha, Cataldo Palmieri, Luigi Emilio Pastormerlo, Andreas Baumbach, Paolo Sganzerla, Corrado Tamburino, Francesco Bruno, Gioel Gabrio Secco, Annamaria Nicolino, Kuang Leon Yew, Gaetano di Palma, Wojciech Wojakowski, Gennaro Sardella, Mauro Rinaldi, Bernardo Cortese, Fabrizio D'Ascenzo
JournalCoronary artery disease (Coron Artery Dis) Vol. 31 Issue 1 Pg. 27-34 (01 2020) ISSN: 1473-5830 [Electronic] England
PMID31658146 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Antibiotics, Antineoplastic
  • Sirolimus
Topics
  • Acute Coronary Syndrome (surgery)
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage)
  • Cardiovascular Diseases (mortality)
  • Coronary Artery Disease (surgery)
  • Drug-Eluting Stents
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (epidemiology)
  • Myocardial Revascularization (statistics & numerical data)
  • Percutaneous Coronary Intervention (methods)
  • Postoperative Complications (epidemiology)
  • Registries
  • Retrospective Studies
  • ST Elevation Myocardial Infarction (surgery)
  • Sirolimus (administration & dosage)
  • Thrombosis (epidemiology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: